Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New dialysis fluid may slow hardening of arteries in kidney patients

NCT ID NCT07163936

Disease control Sponsor: Hospital Clinic of Barcelona Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 17, 2026 · Updated 2 times

Summary

This study tests whether a citrate-based dialysis fluid with extra magnesium can slow or prevent blood vessel hardening in adults on long-term hemodialysis. Eighty stable patients will receive either the new fluid or a standard one for 12 months. Researchers will measure blood markers of calcification risk and monitor heart problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
citrate-based dialysate with magnesium
What this could lead to
If it works, this could point toward a safer dialysis fluid that reduces heart problems and death in kidney patients.
What could go wrong
This is a small, early-stage study with only 80 participants, so results may not apply to everyone. The intervention only changes the dialysis fluid, so any benefit is likely modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years old) on maintenance hemodialysis for more than 3 months * Clinically stable patients with a well-functioning vascular access * Residual urine output ≤ 250 mL/day * Able and willing to provide written informed consent Exclusion Criteria: * Known allergy or intolerance to any component of the dialysates * Active malignancy or infectious/inflammatory disease * Planned living donor kidney transplant before study completion * Current treatment with vitamin K antagonists (coumarins) * Severe hypocalcemia or poorly controlled secondary hyperparathyroidism * Any condition that, in the investigator's judgment, contraindicates participation or affects study compliance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease (CKD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

calcinosis cardiovascular disorder chronic kidney disease Vascular Calcification

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease (CKD) Hemodialysis Vascular calcification

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.